Stone Run Capital LLC continued to hold its stake in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, Holdings Channel reports. The fund owned 1,750 shares of the company’s stock at the end of the first quarter. Stone Run Capital LLC’s holdings in Johnson & Johnson were worth $218,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $117,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares in the last quarter. Taylor Wealth Management Partners boosted its stake in shares of Johnson & Johnson by 19.8% in the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares in the last quarter. Finally, Foundation Resource Management Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $204,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded down 0.35% during trading on Thursday, hitting $132.77. 617,620 shares of the stock were exchanged. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company has a market cap of $356.35 billion, a price-to-earnings ratio of 22.47 and a beta of 0.78. The stock’s 50 day moving average price is $133.23 and its 200-day moving average price is $126.11.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter in the prior year, the business posted $1.74 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Position Maintained by Stone Run Capital LLC” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-position-maintained-by-stone-run-capital-llc/1470683.html.

Several analysts have recently issued reports on the stock. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 target price on the stock. in a research report on Monday, May 8th. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Wells Fargo & Company restated a “market perform” rating and set a $135.00 target price (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Finally, UBS AG restated a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a research report on Monday, May 15th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $133.72.

In other news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.